Clinical Effects of Microecological Agents on Intestinal Dysbacteriosis in Patients with Pancreatic Cancer

Objective: To evaluate the clinical efficacy of microecological agents in the treatment of intestinal dysbacteriosis in patients with pancreatic cancer. Methods: A total of 60 patients with pancreatic cancer and intestinal dysbacteriosis admitted to our hospital from June 1, 2023, to May 31, 2024, were enrolled in this study. They were randomly divided into two groups: the conventional treatment group (n = 30) and the microecological agent group (n = 30). The conventional treatment group received standard treatment, while the microecological agent group received additional treatment with microecological agents. The therapeutic effects and safety were compared between the two groups. Results: Before treatment, there were no significant differences in laboratory indicators between the two groups (P > 0.05). After treatment, the laboratory indicators decreased in both groups, with a more pronounced de-crease observed in the microecological agent group (P < 0.05). The clinical indicators of the microecological agent group were significantly lower than those of the conventional treatment group after treatment (P < 0.05). Additionally, the incidence of adverse reactions in the microecological agent group was significantly lower than that in the conventional treatment group (P < 0.05). Conclusion: Compared with conventional treatment alone, the administration of microecological agents in patients with pancreatic cancer and intestinal dysbacteriosis results in more pronounced therapeutic effects. It can significantly reduce laboratory indicators, shorten defecation and hospitalization time, and accelerate the relief of symptoms and signs, with high safety. Therefore, this treatment approach is worthy of clinical promotion.